68.25
Schlusskurs vom Vortag:
$69.39
Offen:
$69.24
24-Stunden-Volumen:
687.91K
Relative Volume:
1.03
Marktkapitalisierung:
$3.76B
Einnahmen:
$76.81M
Nettoeinkommen (Verlust:
$-162.42M
KGV:
-22.83
EPS:
-2.99
Netto-Cashflow:
$-122.49M
1W Leistung:
+0.15%
1M Leistung:
+8.33%
6M Leistung:
+3.64%
1J Leistung:
+8.38%
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Vergleichen Sie ACLX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ACLX
Arcellx Inc
|
68.25 | 3.76B | 76.81M | -162.42M | -122.49M | -2.99 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-17 | Eingeleitet | Citigroup | Buy |
2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
2024-09-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
2024-03-07 | Eingeleitet | Morgan Stanley | Overweight |
2024-01-04 | Bestätigt | Needham | Buy |
2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
2023-10-30 | Eingeleitet | TD Cowen | Outperform |
2023-10-17 | Eingeleitet | UBS | Buy |
2023-05-18 | Eingeleitet | Truist | Buy |
2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
2023-03-14 | Eingeleitet | Stifel | Buy |
2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
2022-12-13 | Fortgesetzt | BofA Securities | Buy |
2022-10-31 | Eingeleitet | Guggenheim | Buy |
2022-10-27 | Eingeleitet | Needham | Buy |
2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
2022-03-01 | Eingeleitet | BofA Securities | Buy |
2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
What analysts say about Arcellx Inc. stockTriple-digit profit margins - jammulinksnews.com
What drives Arcellx Inc. stock priceUnrivaled growth potential - jammulinksnews.com
Is Arcellx Inc. a good long term investmentFree Trading Strategy Suggestions - jammulinksnews.com
Bank of New York Mellon Corp Cuts Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Principal Financial Group Inc. Sells 184 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Xponance Inc. Acquires 190 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Price - 富途牛牛
Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment - TipRanks
Teacher Retirement System of Texas Decreases Stake in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx; Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market (ACLX) - Seeking Alpha
What makes Arcellx Inc. stock price move sharplyElite Stock Shortlist - Newser
Why Arcellx Inc. stock attracts strong analyst attentionFree High-Accuracy Stock Picks - Newser
GAMMA Investing LLC Buys 252 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Amalgamated Bank Buys 161 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Allspring Global Investments Holdings LLC Has $468,000 Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
How might ACLX's 2025 Q1 EPS forecast affect strategies? - AInvest
Piper Sandler maintains Overweight rating on Arcellx stock amid CAR-T safety study - Investing.com Nigeria
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers - Benzinga
(ACLX) Trading Signals - news.stocktradersdaily.com
Citi initiates Arcellx stock with buy rating on cell therapy potential - Investing.com
Citi initiates Arcellx stock with buy rating on cell therapy potential By Investing.com - Investing.com South Africa
Cancer Cell Market Exclusive Report with Detailed Study Analysis | Abbott Laboratories, Cellectis, Arcellx, GE - newstrail.com
Citigroup Initiates Arcellx at Buy With $110 Price Target - MarketScreener
Arcellx initiated with a Buy at Citi - TipRanks
Arcellx (ACLX): Citi Initiates Buy Rating with Promising Outlook | ACLX Stock News - GuruFocus
Aileen Fernandes | People on The MoveSan Francisco Business Times - The Business Journals
Aileen Fernandes - The Business Journals
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment - TipRanks
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential - TipRanks
ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News - GuruFocus
Arcellx stock maintains buy rating at H.C. Wainwright on launch plans - Investing.com
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating - TipRanks
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning - TipRanks
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):